natgillin/translations-raw huggingface dataset:
If you experience symptoms such as chest tightness, wheezing, severe dizziness, or lightheadedness, seek medical attention immediately. 
Ako osjetite simptome poput stezanja u prsima, piskanja pri disanju, teške omaglice ili ošamućenosti, odmah potražite liječničku pomoć.
Complete drug withdrawal led to loss of remission (return to disease activity) in all three treatment arms (abatacept with methotrexate, abatacept or methotrexate alone) in a majority of patients (Table 3). 
Potpuni prekid terapije doveo je do gubitka remisije (povratka aktivne bolesti) u sve tri liječene skupine (abatacept u kombinaciji s metotreksatom, monoterapija abataceptom ili monoterapija metotreksatom) kod većine bolesnika (Tablica 3).
Clinical efficacy and safety in adult rheumatoid arthritis 
Klinička djelotvornost i sigurnost u odraslih bolesnika s reumatoidnim artritisom
Record the date, time, and site where you inject. 
Zapišite datum, vrijeme i mjesto injekcije.
The results were measured using the Genant-modified total Sharp score (TSS) and its components, the erosion score and joint space narrowing (JSN) score. 
Total Sharp score, TSS) i ocjene njezinih komponenata, ocjene erozije i ocjene suženja zglobnog prostora (engl. joint space narrowing, JSN).
The overall frequency of injection site reactions was 2.6% (19/736) and 2.5% (18/721) for the subcutaneous abatacept group and the subcutaneous placebo group (intravenous abatacept), respectively. 
Ukupna učestalost reakcija na mjestu injekcije iznosila je 2,6% (19/736) u skupini koja je supkutano primala abatacept te 2,5% (18/721) u skupini koja je supkutano primala placebo (intravenski abatacept).
Discontinuation due to an acute infusion-related reaction occurred in 0.3% of patients receiving abatacept and in 0.1% of placebo-treated patients. 
Liječenje je zbog akutne reakcije vezane uz infuziju prekinuto u 0,3% bolesnika koji su primali abatacept i u 0,1% bolesnika koji su primali placebo.
In the placebo-controlled clinical trials, abatacept treatment did not lead to increased autoantibody formation, such as antinuclear and anti-dsDNA antibodies, relative to placebo treatment (see sections 4.8 and 5.3). 
U placebom kontroliranim kliničkim ispitivanjima liječenje abataceptom nije dovelo do povećanog stvaranja autoantitijela, poput antinuklearnih i anti-dsDNK antitijela, u usporedbi s primjenom placeba (vidjeti dijelove 4.8 i 5.3).
Complete drug withdrawal led to loss of remission (return to disease activity) in all three treatment arms (abatacept with methotrexate, abatacept or methotrexate alone) in a majority of patients (Table 4). 
Potpuni prekid terapije doveo je do gubitka remisije (povratka aktivne bolesti) u sve tri liječene skupine (abatacept u kombinaciji s metotreksatom, monoterapija abataceptom ili monoterapija metotreksatom) kod većine bolesnika (Tablica 4).
Table 1: Weekly dose of ORENCIA Body weight of patient 
Tablica 1: Tjedna doza lijeka ORENCIA
The safety and efficacy of abatacept in the ongoing SC study were consistent with the results seen with abatacept in the IV study (see section 5.1 of the ORENCIA solution for injection in pre-filled syringe SmPC for complete study description and results). 
Sigurnost i djelotvornost abatacepta u ispitivanju supkutane formulacije koje je trenutno u tijeku odgovaraju rezultatima opaženima u ispitivanju intravenske formulacije abatacepta (za cjeloviti opis i rezultate ispitivanja vidjeti dio 5.1 sažetka opisa svojstava lijeka za ORENCIA otopinu za injekciju u napunjenoj štrcaljki).
The cumulative immunogenicity frequency to abatacept by the ECL assay with at least one positive sample in the short-term and long-term periods combined was 15.7% (215/1369) while on abatacept, with a mean duration of exposure of 48.8 months, and 17.3% (194/1121) after discontinuation (> 21 days up to 168 days after last dose). 
Kumulativna učestalost frekvencije imunogenosti na abatacept dobivena ECL testom s barem jednim pozitivnim uzorkom u kratkotrajnom i dugotrajnom razdoblju bila je 15,7% (215/1369) tijekom primjene abatacepta, s prosječnim trajanjem izloženosti od 48,8 mjeseci, 17,3% (194/1121) nakon prekida primjene (> 21 dan do 168 dana nakon posljednje doze lijeka).
In a pre- and postnatal development study with abatacept in rats, no undesirable effects were observed in pups of dams given abatacept at doses up to 45 mg/kg, representing 3-fold a human 10 mg/kg exposure based on AUC. 
U istraživanjima prenatalnog i postnatalnog razvoja kod primjene abatacepta u štakora, nisu zabilježeni štetni učinci na mladuncima ženki koje su primale abatacept u dozama do 45 mg/kg, što predstavlja 3 puta veću izloženost od one u ljudi pri dozi od 10 mg/kg, na temelju AUC-a.
Patients treated with abatacept subcutaneously also achieved similar ACR 50 and 70 responses as those patients receiving abatacept intravenously at 6 months. 
Nakon 6 mjeseci, bolesnici koji su abatacept primali supkutano također su postigli odgovore ACR50 i ACR70 u podjednakoj mjeri kao i bolesnici koji su abatacept primali intravenski.
Doses up to 50 mg/kg have been administered intravenously without apparent toxic effect. 
Intravenska primjena doza do 50 mg/kg nije izazvala vidljive toksične učinke.
In studies I, II, and V the efficacy and safety of abatacept compared to placebo were assessed in patients with an inadequate response to methotrexate and who continued on their stable dose of methotrexate. 
U ispitivanjima I, II i V ispitivala se djelotvornost i sigurnost abatacepta u usporedbi s placebom u bolesnika koji nisu dovoljno dobro odgovorili na metotreksat i koji su nastavili uzimati metotreksat u svojim stabilnim dozama.
At the start, your doctor or nurse may inject ORENCIA. 
U početku će Vam injekcije lijeka ORENCIA možda davati liječnik ili medicinska sestra.
This can cause joint damage. 
To može uzrokovati oštećenja zglobova.
Cotton ball or gauze 
Pamučna vata ili gaza
Breast-feeding should be discontinued during treatment with ORENCIA and for up to 14 weeks after the last dose of abatacept treatment. 
Dojenje treba prekinuti tijekom liječenja lijekom ORENCIA i do 14 tjedana nakon posljednje doze abatacepta.
In this study, the steady-state concentrations of abatacept were dose-related. 
U tom su ispitivanju koncentracije abatacepta u stanju dinamičke ravnoteže bile povezane s dozom.
- Slowly add the reconstituted ORENCIA solution from each vial to the infusion bag or bottle using the same silicone-free disposable syringe provided with each vial. 
- - Polako dodajte rekonstituiranu otopinu lijeka ORENCIA iz svake bočice u infuzijsku vrećicu ili bocu, koristeći istu nesilikonsku štrcaljku za jednokratnu uporabu priloženu uz svaku bočicu.
EU/1/07/389/002 2 vials and 2 silicone-free syringes (2 packs of 1) EU/1/07/389/003 3 vials and 3 silicone-free syringes (3 packs of 1) 
EU/1/07/389/002 2 bočice i 2 nesilikonske štrcaljke (2 pakiranja po 1) EU/1/07/389/003 3 bočice i 3 nesilikonske štrcaljke (3 pakiranja po 1)
In SC-II, serious infections were reported in 3.8 % (12/318) of patients treated with abatacept SC weekly, none of which led to discontinuation and in 5.8 % (19/328) of patients treated with adalimumab SC every-other-week, leading to 9 discontinuations in the 24-month period. 
U ispitivanju SC-II su tijekom 24-mjesečnog razdoblja ozbiljne infekcije prijavljene u 3,8% (12/318) bolesnika liječenih abataceptom primijenjenim supkutano jedanput na tjedan (niti jedna od njih nije uzrokovala prekid liječenja) te u 5,8% (19/328) bolesnika liječenih adalimumabom primijenjenim supkutano jedanput svaka dva tjedna (u 9 slučajeva dovele su do prekida liječenja).
ORENCIA is available in the following presentations: - pack of 4 pre-filled pens and multipack containing 12 pre-filled pens (3 packs of 4). 
ORENCIA je dostupna u sljedećim pakiranjima: - pakiranje od 4 napunjene brizgalice i višestruko pakiranje koje sadrži 12 napunjenih brizgalica (3 pakiranja po 4).
DO NOT RECAP the Pre-filled Syringe, as this may damage the needle. 
NEMOJTE VRAĆATI ZATVARAČ na napunjenu štrcaljku jer tako možete oštetiti iglu.
There were no adverse reactions that occurred at ≥ 2% in either treatment group during the 24-week placebocontrolled period. 
Ni u jednoj od tih dviju liječenih skupina nijedna se nuspojava nije javila u ≥ 2% bolesnika tijekom 24-tjednog placebom kontroliranog razdoblja.
Study SC-I: Pre-filled pen sub-study 
Ispitivanje SC-I: podispitivanje primjene napunjenom brizgalicom
Study SC-I compared the immunogenicity to abatacept following subcutaneous or intravenous administration as assessed by ELISA assay. 
U ispitivanju SC-I uspoređivala se imunogenost na abatacept nakon supkutane odnosno intravenske primjene, primjenom ELISA testa.
Table 10: 
Tablica 10:
In rats and rabbits, abatacept exposure was up to 29-fold a human 10 mg/kg exposure based on AUC. 
U štakora i kunića je izloženost abataceptu, na temelju AUC-a, bila do 29 puta veća od izloženosti u ljudi pri dozi od 10 mg/kg.
Placebo +DMARDsb 
Placebo +DMARD-i b
Paediatric patients weighing 75 kg or more should be administered ORENCIA following the adult dosing regimen, not to exceed a maximum dose of 1,000 mg. ORENCIA should be administered as a 30-minute intravenous infusion. 
U pedijatrijskih bolesnika tjelesne težine 75 kg ili više lijek ORENCIA treba primjenjivati prema režimu doziranja za odrasle, no ne smije se prekoračiti maksimalna doza od 1000 mg.
Don't put the needle cover back on the needle once removed. 
Nemojte vraćati poklopac na iglu nakon što ga skinete.
If you miss your dose within three days of when you are supposed to take it, take your dose as soon as you remember and then follow your original dosing schedule on your chosen day. 
Ako ste propustili dozu, a nije prošlo više od 3 dana od kada ste je trebali dobiti, primijenite je čim se sjetite, a zatim nastavite primjenjivati doze prema dotadašnjem rasporedu.
Before you use ORENCIA, your doctor may examine you for hepatitis. 
Prije nego što primijenite lijek ORENCIA, liječnik će Vas možda testirati na hepatitis.
The recommended dose of ORENCIA for adults with rheumatoid arthritis or psoriatic arthritis is 125 mg abatacept given every week regardless of weight. 
Preporučena doza lijeka ORENCIA za odrasle osobe s reumatoidnim artritisom ili psorijatičnim artritisom je 125 mg abatacepta svakoga tjedna, neovisno o tjelesnoj težini.
- Remove the syringe and needle after 10 mL of water for injections have been injected into the vial. 
- - Izvadite štrcaljku i iglu nakon što ste 10 ml vode za injekcije ubrizgali u bočicu.
Remove the pre-filled syringe from the injection site and let go of the pinched skin. 
Maknite štrcaljku s mjesta injekcije i pustite kožni nabor.
If a single IV infusion is given to initiate treatment (IV loading dose before SC administration), the first 125 mg abatacept SC should be administered within a day of the IV infusion, followed by the weekly 125 mg abatacept SC injections (for the posology of the intravenous loading dose, please refer to section 4.2 of ORENCIA 250 mg powder for concentrate for solution for infusion). 
Ako se za početak liječenja daje jednokratna intravenska infuzija (intravenska udarna doza prije supkutane primjene), prvu supkutanu dozu abatacepta od 125 mg treba primijeniti unutar jednoga dana od intravenske infuzije, nakon čega se liječenje nastavlja supkutanim injekcijama abatacepta u dozi od 125 mg jedanput na tjedan (za doziranje intravenske udarne doze, vidjeti dio 4.2 Sažetka opisa svojstava za lijek ORENCIA 250 mg prašak za koncentrat za otopinu za infuziju).
62% 73%*** 40% NAd 
62% 73%*** 40% NDd
If you have questions about this product, please read the Package Leaflet. 
Ako imate pitanja o ovom lijeku, pročitajte uputu o lijeku.
In the 2 to 5 year age cohort, the overall rate of seropositivity during the cumulative period including post abatacept follow-up was 15.2% (7/46): 10.9% (5/46) on treatment and 37.5% (3/8) after discontinuation of abatacept (≥ 28 days after the last dose). 
U kohorti ispitanika od 2 do 5 godina starosti, ukupna stopa seropozitivnosti tijekom kumulativnog razdoblja, uključujući praćenje nakon abatacepta iznosila je 15,2% (7/46): 10,9% (5/46) na terapiji i 37,5% (3/8) nakon prestanka primjene abatacepta
Reconstitution of vials: under aseptic conditions, reconstitute each vial with 10 mL of water for injections, using the silicone-free disposable syringe provided with each vial and an 18-21 gauge needle. 
Priprema bočica: u aseptičkim uvjetima pripremite svaku bočicu s 10 ml vode za injekcije, koristeći nesilikonsku štrcaljku za jednokratnu uporabu priloženu uz svaku bočicu i iglu veličine 18-21 G.
Hold the body of the pre-filled syringe in your hand using your thumb and index finger. 
Uhvatite tijelo napunjene štrcaljke palcem i kažiprstom.
Listed in Table 1 are adverse reactions observed in clinical trials and post-marketing experience presented by system organ class and frequency, using the following categories: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000). 
Tablici 1 nuspojave primijećene u kliničkim ispitivanjima te nakon stavljanja lijeka u promet prikazane su prema klasifikaciji organskih sustava i učestalosti pojavljivanja, prema sljedećim kategorijama: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100), rijetko (≥ 1/10 000 i < 1/1000), vrlo rijetko (< 1/10 000).
- Do not use the vial if the vacuum is not present. 
- - Nemojte koristiti bočicu, ako u njoj nije vakuum.
In the 6 to 17 year age cohort, the overall rate of seropositivity during the cumulative period including post abatacept follow-up was 4.7% (8/172): 2.3% (4/172) on treatment and 13.6% (6/44) after discontinuation of abatacept (≥ 28 days after the last dose). 
U kohorti ispitanika od 6 do 17 godina starosti, ukupna stopa seropozitivnosti tijekom kumulativnog razdoblja, uključujući praćenje nakon abatacepta iznosila je 4,7% (8/172): 2,3% (4/172) na terapiji i 13,6% (6/44) nakon prestanka primjene abatacepta
Lower respiratory tract infection (including bronchitis), urinary tract infection, herpes infections (including herpes simplex, oral herpes, and herpes zoster), pneumonia, influenza Uncommon Tooth infection, onychomycosis, sepsis, muskuloskeletal infections, skin abscess, pyelonephritis, rhinitis, ear infection 
često infekcija donjeg dijela respiratornog trakta (uključujući bronhitis), infekcija urinarnog trakta, infekcije herpes virusima (uključujući herpes simplex, oralni herpes i herpes zoster), pneumonija, influenca manje često infekcija zuba, onihomikoza, sepsa, mišićnokoštane infekcije, kožni apsces, pijelonefritis, rinitis, infekcija uha rijetko tuberkuloza, bakterijemija, gastrointestinalne infekcije, upalna bolest zdjelice
The safety and efficacy of ORENCIA solution for injection in pre-filled pen for subcutaneous administration in children below 18 years of age have not been established. 
Sigurnost i djelotvornost supkutane primjene ORENCIA otopine za injekciju u napunjenoj brizgalici u djece mlađe od 18 godina nisu ustanovljene.
In SC-III, increased rates of immunogenicity were observed in subjects tested during 6 months of complete drug withdrawal in the abatacept+MTX and abatacept monotherapy groups (37.7% [29/77] and 44.1% [27/59], respectively) with generally low titer antibody responses. 
U ispitivanju SC-III primijećene su povećane stope imunogenosti u ispitanika u kojih se provodilo testiranje tijekom razdoblja od 6 mjeseci nakon potpunog prekida terapije u skupini koja je primala abatacept + MTX i onoj liječenoj monoterapijom abataceptom (37,7% [29/77] odnosno 44,1% [27/59]), uz načelno nizak titar odgovora protutijela.
STEP 3: Inject ORENCIA 
KORAK 3: Injicirajte lijek ORENCIA
The recommended dose of ORENCIA for adults with rheumatoid arthritis or psoriatic arthritis is 125 mg given every week regardless of weight. 
Preporučena doza lijeka ORENCIA za odrasle osobe s reumatoidnim artritisom ili psorijatičnim artritisom je 125 mg svakoga tjedna, neovisno o tjelesnoj težini.
Structural joint damage was assessed radiographically over a two-year period in studies II, and VI. 
Strukturno oštećenje zglobova ocjenjivano je radiografski tijekom dvogodišnjeg razdoblja u ispitivanjima II i VI.
Listed in Table 2 are adverse reactions observed in clinical trials and post-marketing experience presented by system organ class and frequency, using the following categories: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000). 
Tablici 2 nuspojave primijećene u kliničkim ispitivanjima te nakon stavljanja lijeka u promet prikazane su prema klasifikaciji organskih sustava i učestalosti pojavljivanja, prema sljedećim kategorijama: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100), rijetko (≥ 1/10 000 i < 1/1000), vrlo rijetko (< 1/10 000).
Keep Pen and the disposal container out of the reach of children. 
Brizgalicu i spremnik za odlaganje čuvajte izvan dohvata djece.
The ACR responses in study V were consistent with the DAS28 score. 
V bili su u skladu s rezultatom indeksa DAS28.
Upper respiratory tract infection (including tracheitis, nasopharyngitis, and sinusitis) 
Infekcije i infestacije vrlo često infekcija gornjeg dijela respiratornog trakta (uključujući traheitis, nazofaringitis i sinusitis)
In the cumulative period 7,044 patients treated with abatacept during 21,011 patient-years (of which over 1,000 were treated with abatacept for over 5 years), the incidence rate of malignancy was 1.2 (1.1, 1.4) per 100 patient-years, and the annualised incidence rates remained stable. 
U kumulativnom su razdoblju 7044 bolesnika liječena abataceptom tijekom 21 011 bolesnik-godina (od kojih je više od 1000 liječeno abataceptom dulje od 5 godina), a stopa incidencije zloćudnih bolesti iznosila je 1,2 (1,1; 1,4) na 100 bolesnik-godina te je ostala stabilna na godišnjoj razini.
Clinical efficacy and safety in adult psoriatic arthritis 
Klinička djelotvornost i sigurnost u odraslih bolesnika s psorijatičnim artritisom
ORENCIA solution for injection in pre-filled syringe has not been studied in children and adolescents under 2 years of age. 
ORENCIA otopina za injekciju u napunjenoj štrcaljki nije ispitivana u djece i adolescenata mlađih od 2 godine.
You can discard the cap in your household waste after the injection. 
Nakon injekcije, zatvarač možete odložiti u kućni otpad.
Abatacept has been studied in patients with pJIA in two clinical trials (pJIA SC study and pJIA IV study). 
Abatacept se ispitivao u bolesnika s pJIA-om u dvama kliničkim ispitivanjima (ispitivanje pJIA SC i ispitivanje pJIA IV).
Comprehensive instructions for the preparation and administration of ORENCIA in a pre-filled syringe are given in the package leaflet and “Important instructions for use”. 
Cjelovite upute za pripremu i primjenu lijeka ORENCIA u napunjenoj brizgalici navedene su u uputi o lijeku i 'Važnim uputama za uporabu'.
Very common (may affect more than 1 in 10 people): infections of the upper airway (including infections of the nose, throat and sinuses). 
Vrlo često (mogu se javiti u više od 1 na 10 osoba): infekcije gornjih dišnih putova (uključujući infekcije nosa, grla i sinusa).
It is unknown whether abatacept is excreted in human milk. 
Nije poznato izlučuje li se abatacept u majčino mlijeko u ljudi.
Write down the date, time, and specific part of your body where you injected yourself. 
Zapišite datum, vrijeme i područje tijela u koje ste primijenili injekciju.
At 12 months, the incidence of AE of infections were 59.6% (93), 68.5% (113), and the incidence of serious AE of infections were 1.9% (3) and 8.5% (14) for abatacept and infliximab groups, respectively. 
Nakon 12 mjeseci je incidencija infekcija kao nuspojave u skupini liječenoj abataceptom iznosila 59,6% (93), a u skupini liječenoj infliksimabom 68,5% (113), dok je incidencija infekcija kao ozbiljne nuspojave u skupini liječenoj abataceptom bila 1,9% (3), a u skupini liječenoj infliksimabom 8,5% (14).
The mean (range) for cmin and cmax at steady state observed after 85 days of treatment was 32.5 mcg/mL (6.6 to 113.8 mcg/mL) and 48.1 mcg/mL (9.8 to 132.4 mcg/mL), respectively. 
Prosječne vrijednosti (raspon) Cmin i Cmax u stanju dinamičke ravnoteže zabilježene nakon 85 dana liječenja bile su 32,5 µg/ml (6,6 do 113,8 µg/ml), odnosno 48,1 µg/ml (9,8 to 132,4 µg/ml).
Do not remove the needle cover while allowing the pre-filled syringe to reach room temperature. 
Nemojte skidati poklopac igle dok čekate da se napunjena štrcaljka ugrije na sobnu temperaturu.
The adjusted geometric mean of abatacept at steady state trough concentration (Cminss) was 25.3 mcg/mL for the subcutaneous pre-filled pen and 27.8 mcg/mL for the subcutaneous pre-filled syringe with a ratio of 0.91 [90% CI: 0.83, 1.00]. 
Prilagođena srednja geometrijska vrijednost najniže koncentracije abatacepta u stanju dinamičke ravnoteže (Cminss) iznosila je 25,3 µg/ml za supkutanu formulaciju u napunjenoj brizgalici te 27,8 µg/ml za supkutanu formulaciju u napunjenoj štrcaljki, uz omjer od 0,91 [90% CI: 0,83; 1,00].
After 24 months, adverse reactions were reported in 41.5% (132/318) and 50% (164/328) of abatacept and adalimumab-treated patients. 
Nakon 24 mjeseca nuspojave su prijavljene u 41,5% (132/318) bolesnika liječenih abataceptom i 50% (164/328) bolesnika liječenih adalimumabom.
Abatacept has been studied in patients with active psoriatic arthritis in two placebo-controlled clinical trials (341 patients with abatacept, 253 patients with placebo) (see Section 5.1). 
Abatacept se ispitivao u bolesnika s aktivnim psorijatičnim artritisom u dvama placebom kontroliranim kliničkim ispitivanjima (341 bolesnik primao je abatacept, a 253 placebo) (vidjeti dio 5.1).
Remove the syringe and needle after 10 mL of water for injections have been injected into the vial. 
Izvadite štrcaljku i iglu nakon što ste 10 ml vode za injekcije ubrizgali u bočicu.
ORENCIA should be administered weekly at a dose of 125 mg by subcutaneous (SC) injection without the need for an intravenous (IV) loading dose. 
ORENCIA se primjenjuje supkutanom (s.c.) injekcijom u dozi od 125 mg jedanput na tjedan, bez potrebe za udarnom intravenskom (i.v.) dozom.
Twenty-two of 48 evaluable patients showed significant neutralizing activity. 
Značajno neutralizirajuća aktivnost utvrđena je u 22 od 48 bolesnika dostupnih za evaluaciju.
During the 24-month cumulative period of the pJIA SC study (4-month short term period plus 20-month extension period), a higher frequency of infections was reported in the 2 to 5 year age cohort (87.0%) compared to that reported in the 6 to 17 year age cohort (68.2%). 
Tijekom 24-mjesečnog kumulativnog razdoblja ispitivanja pJIA SC studije (4-mjesečno kratkoročno razdoblje plus 20-mjesečno razdoblje nastavka), veća učestalost infekcija prijavljena je u kohorti od 2 do 5 godina starosti (87,0%) u usporedbi s onim prijavljenim u kohorti u dobi od 6 do 17 godina starosti (68,2%).
ORENCIA, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients when the response to previous DMARD therapy including MTX has been inadequate and for whom additional systemic therapy for psoriatic skin lesions is not required. 
ORENCIA je, sama ili u kombinaciji s metotreksatom (MTX), indicirana za liječenje aktivnog psorijatičnog artritisa (PsA) u odraslih bolesnika u kojih odgovor na prethodnu terapiju DMARD-ima, uključujući MTX, nije bio dovoljno dobar i kojima nije potrebna dodatna sistemska terapija za psorijatične kožne lezije.
In addition, inflammation of the thyroid and pancreas was frequently seen in both juvenile and adult rats exposed to abatacept. 
Osim toga, i u mladih i u odraslih štakora izloženih abataceptu često su zabilježene upala štitnjače i gušterače.
Release skin pinch. 
Otpustite nabor kože.
The proportion of patients who discontinued treatment due to ARs was 3.0% for abatacept-treated patients and 2.0% for placebo-treated patients. 
Udio bolesnika koji su prekinuli liječenje zbog nuspojava iznosio je 3,0% među bolesnicima liječenima abataceptom te 2,0% među bolesnicima koji su primali placebo.